Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Vitalhub Corp (VHIBF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Vitalhub Corp $2.75, price $5.40, upside -49.1%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
VC
Broad data
Sep 24, 2026
Broad data
Sep 24, 2026
Vitalhub Corp
VHIBF · USWeakest SetupStrongly overvalued and low quality.
!Fair value $2.75 · Strongly overvalued (−49.1%)
!Quality 45/100
✓Healthy Growth (revenue 5y +51.2 %/yr)
!Thin margins · 6.1% net margin (TTM)
✓Low debt · generates free cash flow
!Moderate moat 45/100
Watch Vitalhub Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $1.69 – $10.32 · fair‑value band $1.84 – $4.15 · the $5.40 price screens above the $2.75 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Vitalhub Corp., together with its subsidiaries, provides technology and software solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally.
Show more
Vitalhub Corp., together with its subsidiaries, provides technology and software solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. The company offers patient flow, operational visibility, and patient journey optimization solutions for hospital and integrated health environments, including SHREWD, Intouch with Health, Strata Health, MedCurrent, Beautiful Information, My Pathway, BookWise Solutions, Jayex Acute, MCAP, and Oculys. It also provides electronic healthcare record, case management, care coordination, and optimization solutions to inpatient/outpatient care providers, long-term care, and community and social services focused organizations, such as TREAT, CaseWORKS, clarity, Community Data Solutions, S12, B Care, DOCit, hicom, Clarity Healthcare Solutions, and Pirouette. In addition, the company offers a workforce automation and compliance suite that integrates and centralizes workforce and compliance data, which includes Hicom, Premier IT, and BookWise. Vitalhub Corp. was founded in 2010 and is headquartered in Toronto, Canada.
Stock analysis
Vitalhub Corp (VHIBF) currently trades at $5.40, while our model-based Fair Value estimate is $2.75, 49.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $3.15 per share, and 1 of the 24 models we run sit above the $5.40 price.
Bear case: the Multiples group reads lowest at $1.49, and 23 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $1.84 (bear) to $4.15 (bull), the price of $5.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Vitalhub Corp reported revenue of C$109M in FY2025 versus C$24.7M in FY2021, a compound +45.0%/yr. Reported net income was C$6.1M in FY2025.
Key figures
Market cap $341M · P/E ratio 67.5 · P/S ratio 3.79 · EPS (TTM) $0.0800 · Net margin 5.6% · Return on equity 3.3% · Return on assets (EBIT) 3.7% · Operating margin 13.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (medium confidence).
What moves the price
The share trades about 36% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −49%, VHIBF screens richer than that median.
Fair Value models
Bear $1.84
Fair Value $2.75
Bull $4.15
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0605 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$1.84
$2.39
$4.05
77
Growth DCF
$1.77
$2.59
$3.88
76
EPV
$1.61
$1.74
$1.85
74
All 24 models by family
DCF Models
FCF DCF
$1.84
$2.39
$4.05
77
Owner Earnings
$3.02
$5.57
$10.31
71
5Y Revenue Exit
$1.93
$2.93
$5.01
68
5Y EBITDA Exit
$2.90
$4.87
$8.75
70
5Y P/E Exit
$1.80
$3.15
$4.97
67
10Y Revenue Exit
$1.86
$3.40
$4.40
65
10Y EBITDA Exit
$2.55
$5.28
$10.17
62
10Y P/E Exit
$1.82
$3.13
$5.24
60
Earnings-Based
Graham-Dodd
$0.4600
$3.22
$4.51
61
Lynch FV
$1.66
$2.37
$3.09
59
PEG = 1.0
$1.66
$2.37
$3.09
55
EPV
$1.61
$1.74
$1.85
74
Multiples
P/E Multiple
$1.12
$1.49
$1.86
63
P/S Multiple
$0.8600
$1.15
$1.44
58
P/B Multiple
$0.8600
$1.15
$1.44
55
EV/EBIT
$2.36
$2.93
$3.51
66
EV/EBITDA
$3.35
$4.25
$5.15
67
EV/Revenue
$1.87
$2.39
$2.92
54
Asset-Based
NCAV (Graham)
$1.48
$1.98
$2.95
54
Growth DCF
Growth DCF
$1.77
$2.59
$3.88
76
Rev-Margin DCF
$2.07
$3.26
$5.73
68
Economic Profit
Residual Income
$1.97
$1.83
$1.79
68
ROIC Compounder
$1.61
$1.74
$1.85
70
Growth Earnings
Growth-Adj P/E
$2.21
$3.15
$4.10
65
Notify me when VHIBF reaches fair value
Put VHIBF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
45/100
Of which business quality 49 · Market factors (momentum, volatility) 37
Profitability
28
Margins and returns on capital today
Quality Growth
64
Are margins and returns improving?
Cashflow
59
Earnings quality: real cash, not paper profit
Fin. Strength
90
Balance sheet, leverage, solvency risk
Investment
33
Disciplined investing over empire-building
Low Volatility
59
Calm price path (market factor)
Momentum
39
Price trend over the last 3–12 months (market factor)
52W Momentum
10
Distance to the 52-week high (market factor)
Net Issuance
0
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+58.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+76.7%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +21.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+21.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−3% → 11%
⚠ Rate on operating basis: 2025 sits 70% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+31.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CAD, Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about +28.5% a year for the price and +7.5% for the forecasts.
Forecast 2026 (sales)+20.0%
Forecast 2027 (sales)+8.6%
Projected 2028 (sales)+7.8%
Projected 2029 (sales)+6.9%
Projected 2030 (sales)+6.1%
VHIBF screens overvalued: fair value 49% below the price. Compare with Veeva Systems Inc →
Compare Vitalhub Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 128 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Health Information Services median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $278.57 | $306.43 | +10% |
| Pro Medicus Limited PME | A$161.00 | A$84.62 | −47% |
| BrightSpring Health Services, Inc BTSG | $56.54 | $25.86 | −54% |
| Hinge Health, Inc HNGE | $95.57 | $51.25 | −46% |
| HealthEquity, Inc HQY | $88.44 | $97.28 | +10% |
| Waystar Holding WAY | $24.70 | $27.17 | +10% |
| Doximity, Inc DOCS | $26.35 | $31.41 | +19% |
| XtalPi Holdings 2228 | HK$7.75 | HK$1.50 | −81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,779 | ₹1,883 | +6% |
| Privia Health Group PRVA | $19.62 | $5.02 | −74% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Vitalhub Corp (VHIBF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $2.75 versus a price of $5.40, about −49% upside (overvalued).
What is the fair value of VHIBF?
Our model-based fair value for Vitalhub Corp is $2.75 (as of Sep 24, 2026), built from audited fundamentals. The current price: $5.40.
What is the quality score of VHIBF?
Vitalhub Corp has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vitalhub Corp (VHIBF)?
Our model-based price target is the fair value of $2.75 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $1.84, optimistic scenario $4.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Vitalhub Corp stock forecast for 2026?
Our models put fair value at $2.75, about −49% upside versus a price of $5.40 (overvalued). Cautious scenario $1.84, optimistic scenario $4.15. The calculation is refreshed regularly with new filings.
What is the revenue of Vitalhub Corp (VHIBF)?
Vitalhub Corp reported trailing-twelve-month revenue of about C$119M (latest available figure, as of Sep 24, 2026).
What growth is priced into Vitalhub Corp (VHIBF)?
For today's price to be fair in a discounted-cash-flow model, Vitalhub Corp would have to grow free cash flow by +31.2 % per year for five years (discount rate 10.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +51.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of VHIBF use?
Our models discount Vitalhub Corp at 10.6 %: a base by market capitalisation (small), damped by beta 0.77, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vitalhub Corp that is +31.2 % per year a year over ten years, using the same discount rate (10.6 %) and the same formula as our fair value.
How much growth has Vitalhub Corp (VHIBF) delivered so far?
Over the past 5 years revenue at Vitalhub Corp grew +51.2 % a year. The price currently implies +31.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vitalhub Corp (VHIBF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Vitalhub Corp (+31.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vitalhub Corp (VHIBF)?
The free-cash-flow yield on the price is 1.62 %: that much free cash flow Vitalhub Corp produces per unit of market value. When it exceeds the discount rate of our models (10.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vitalhub Corp (VHIBF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vitalhub Corp it is $2.75 per share (as of Sep 24, 2026), against a price of $5.40. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Vitalhub Corp stock overvalued or undervalued in 2026?
As of Sep 24, 2026, VHIBF trades above its calculated fair value: price $5.40, fair value $2.75, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VHIBF?
No. The price is what the market pays today ($5.40); the fair value is what the company's own numbers justify ($2.75). For Vitalhub Corp the two are $2.65 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vitalhub Corp worth?
The market values Vitalhub Corp at about $341M (market capitalisation, as of Sep 24, 2026). Per share that is $5.40; our models calculate a fair value of $2.75 per share.
What do the bullish and bearish scenarios say about VHIBF?
Our models span a range for Vitalhub Corp: cautious scenario $1.84, base $2.75, optimistic $4.15 per share (as of Sep 24, 2026, price $5.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VHIBF?
Vitalhub Corp trades at a price-to-earnings ratio of 67.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $2.75 is built from several models across several years. Other multiples: PEG 3.3, P/B 1.2, P/S 2.6, EV/EBITDA 10.8.
What is the PEG ratio of VHIBF?
The PEG ratio of Vitalhub Corp is 3.28 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Vitalhub Corp (VHIBF)?
Balance-sheet figures for Vitalhub Corp (as of Sep 24, 2026): return on equity 3.3%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is VHIBF from its 52-week high?
Vitalhub Corp trades at $5.40, about 36% below its 52-week high of $8.38 and 16% above the low of $4.65 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $2.75 is for.
Which stocks are comparable to Vitalhub Corp?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vitalhub Corp stock attractive at the current price?
The data as of Sep 24, 2026: price $5.40, calculated fair value $2.75 (−49%), Quality Score 45/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VHIBF calculated?
We run Vitalhub Corp through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.75, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Vitalhub Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vitalhub Corp (VHIBF)?
The closing price on Oct 2, 2026 was $5.40. Our model-based fair value is $2.75, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vitalhub Corp right now?
The price sits above even our optimistic bull case ($4.15). The favourable scenario is already priced in. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($1.84 to $4.15) leaves room in how you read the outcome.
Key figures of Vitalhub Corp
How large is the market capitalisation of Vitalhub Corp (VHIBF)?
The market capitalisation of Vitalhub Corp is $341M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vitalhub Corp (VHIBF)?
The price-to-sales ratio of Vitalhub Corp is 3.79 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vitalhub Corp (VHIBF)?
Earnings per share at Vitalhub Corp are $0.0800 (price ÷ EPS = P/E 67.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vitalhub Corp (VHIBF)?
The net margin of Vitalhub Corp is 5.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vitalhub Corp (VHIBF)?
The return on equity (ROE) of Vitalhub Corp is 3.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vitalhub Corp (VHIBF)?
On an EBIT basis the return on assets of Vitalhub Corp is 3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vitalhub Corp (VHIBF)?
The operating margin of Vitalhub Corp is 13.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vitalhub Corp (VHIBF)?
Revenue at Vitalhub Corp is growing +47.2% versus a year earlier (3y avg +39.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vitalhub Corp (VHIBF)?
Earnings per share at Vitalhub Corp are growing +86.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Vitalhub Corp in the live analysis
One click puts Vitalhub Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.